Page 7 - Serum Institute Of India

Sustainable pricing

Govt and vaccine makers should be transparent

Covid-19 vaccine Covaxin at Rs 150 not sustainable: Bharat Biotech

Higher price in private market required to offset part of the costs, argues firm

India Coronavirus Dispatch: Lowest daily jump in cases since March 31

New Covid strain on world radar stems from Delta variant, Covaxin is world's third costliest jab and more-news relevant to India's fight against the pandemic

Novavax Covid-19 shot shows 90% efficacy, Serum Institute starts production

On track to make 100 mn doses per month by Q3 of 2021

Novavax's coronavirus vaccine shows 90% efficacy in late stage trial

The US-based firm has partnered with Serum Institute to produce shots locally in India

Setbacks to Serum Institute of India leave world short of Covid shots

The world's largest vaccine maker has been dogged by problems, from a ban on exports to a factory fire, that have hampered its ability to fill orders

Centre fixes maximum price for Covid-19 vaccines at private hospitals

The CoWIN system would also ensure that the prices declared by various private vaccination centres do not exceed the maximum price

Covid-19 vaccination: Govt books 440 million doses with 30% advance

250 mn Covishield and 190 mn Covaxin doses meant for Aug-Dec period

Govt caps maximum price of Covishield, Covaxin, Sputnik V for pvt hospitals

The govt has set the maximum price private hospitals can charge for the three Covid vaccines currently available in the country -- Covishield Rs 780 per dose, Covaxin Rs 1,410, and Sputnik V Rs 1,145

Covid-19 vaccine manufacturers, private hospitals face revenue loss

Back-of-the-envelope calculations show that Serum Institute of India (SII) will lose revenues worth Rs 26.25 crore a month, while Bharat Biotech would lose to the tune of Rs 45 crore a month

Free Covid-19 vaccine for all above 18 years from June 21: PM Modi

Of the total vaccine availability, 75 per cent will be procured by the Centre and the remaining 25 per cent will continue to be available for private hospitals.

Covid-19 pandemic: Second Covishield dose before 84 days allowed for some

The Co-WIN system will soon provide the facility for the administration of the second dose in such exceptional cases, the ministry said

Covishield shows better antibody response than Covaxin, says study

The study was aimed at analysing the antibody response after two complete doses of Covishield and Covaxin in Indians

Do not politicise GST Council: Finance Minister Nirmala Sitharaman

The government is conscious of the intensity of the second wave of Covid-19 and is assessing its full impact before coming out with further packages and interventions, says FM Sitharaman

Serum Institute gets DCGI's nod to manufacture Covid jab Sputnik V in India

Russia's Sputnik V vaccine is currently being manufactured by Dr Reddy's Laboratories in India.

Covid-19 pandemic: Serum Institute seeks indemnity for jab again

In talks with RDIF to manufacture Sputnik V in India

After Pfizer, Serum Institute seeks indemnity over Covid vaccine: Report

Amid discussions over possible legal protection to foreign vaccine manufacturers Pfizer and Moderna over their COVID-19 jabs in India, SII has also sought protection against liabilities

Serum Institute applies to DCGI to manufacture Covid vaccine Sputnik V

The Serum Institute of India has applied to DCGI seeking permission to manufacture Covid-19 vaccine Sputnik V in the country

Decoded: Who can get antibody cocktail for Covid-19 and how it works

Used to treat only mild to moderate disease in high-risk Covid-19 patients, doctors feel the treatment can bolster the fight against severe disease

Bombay HC asks Maha govt to address security concerns raised by Serum CEO

The Bombay High Court said the Maharashtra government must assure SII CEO of requisite security in the wake of alleged threats to him over the supply of the Covishield vaccine